A detailed history of Shell Asset Management CO transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 85,627 shares of GILD stock, worth $7.72 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares
85,627
Previous 85,455 0.2%
Holding current value
$7.72 Million
Previous $5.86 Million 22.45%
% of portfolio
0.32%
Previous 0.27%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$66.59 - $83.99 $11,453 - $14,446
172 Added 0.2%
85,627 $7.18 Million
Q1 2024

Jul 31, 2024

SELL
$71.58 - $87.29 $328,695 - $400,835
-4,592 Reduced 5.1%
85,455 $5.86 Million
Q1 2024

May 14, 2024

BUY
$71.58 - $87.29 $109,087 - $133,029
1,524 Added 1.72%
90,047 $6.6 Million
Q4 2023

Feb 14, 2024

SELL
$73.27 - $83.09 $1.47 Million - $1.66 Million
-20,006 Reduced 18.43%
88,523 $7.17 Million
Q3 2023

Nov 08, 2023

SELL
$73.94 - $80.67 $94,051 - $102,612
-1,272 Reduced 1.16%
108,529 $8.13 Million
Q2 2023

Jul 28, 2023

BUY
$76.01 - $86.7 $1.03 Million - $1.18 Million
13,585 Added 14.12%
109,801 $8.46 Million
Q1 2023

May 15, 2023

BUY
$77.31 - $88.08 $13,915 - $15,854
180 Added 0.19%
96,216 $7.98 Million
Q4 2022

Feb 07, 2023

BUY
$62.32 - $89.47 $1.22 Million - $1.75 Million
19,551 Added 25.56%
96,036 $8.25 Million
Q3 2022

Nov 14, 2022

SELL
$59.54 - $68.01 $913,819 - $1.04 Million
-15,348 Reduced 16.71%
76,485 $4.72 Million
Q2 2022

Aug 09, 2022

SELL
$57.72 - $65.01 $871,110 - $981,130
-15,092 Reduced 14.11%
91,833 $5.68 Million
Q1 2022

May 04, 2022

BUY
$57.92 - $72.58 $5,386 - $6,749
93 Added 0.09%
106,925 $6.36 Million
Q4 2021

Feb 09, 2022

SELL
$64.88 - $73.64 $3.78 Million - $4.29 Million
-58,249 Reduced 35.29%
106,832 $7.76 Million
Q3 2021

Nov 04, 2021

SELL
$67.69 - $73.03 $6.77 Million - $7.3 Million
-100,009 Reduced 37.73%
165,081 $11.5 Million
Q2 2021

Aug 12, 2021

SELL
$63.47 - $69.35 $910,667 - $995,033
-14,348 Reduced 5.13%
265,090 $18.3 Million
Q1 2021

May 10, 2021

SELL
$60.0 - $68.46 $2.49 Million - $2.84 Million
-41,476 Reduced 12.92%
279,438 $18.1 Million
Q4 2020

Feb 16, 2021

BUY
$56.65 - $64.55 $5 Million - $5.7 Million
88,348 Added 37.99%
320,914 $18.7 Million
Q3 2020

Nov 13, 2020

SELL
$62.1 - $78.08 $255,789 - $321,611
-4,119 Reduced 1.74%
232,566 $14.7 Million
Q2 2020

Aug 10, 2020

BUY
$72.34 - $84.0 $7.45 Million - $8.65 Million
102,929 Added 76.95%
236,685 $18.2 Million
Q1 2020

May 11, 2020

SELL
$62.63 - $80.22 $996,631 - $1.28 Million
-15,913 Reduced 10.63%
133,756 $10 Million
Q4 2019

Feb 13, 2020

BUY
$61.62 - $67.78 $4.36 Million - $4.8 Million
70,810 Added 89.79%
149,669 $9.73 Million
Q3 2019

Nov 12, 2019

SELL
$62.51 - $69.0 $687 - $759
-11 Reduced 0.01%
78,859 $5 Million
Q2 2019

Aug 12, 2019

SELL
$61.87 - $69.38 $303,967 - $340,863
-4,913 Reduced 5.86%
78,870 $5.33 Million
Q1 2019

May 09, 2019

BUY
$62.53 - $70.05 $48,648 - $54,498
778 Added 0.94%
83,783 $5.45 Million
Q4 2018

Feb 13, 2019

SELL
$60.54 - $79.0 $699,479 - $912,766
-11,554 Reduced 12.22%
83,005 $5.19 Million
Q3 2018

Nov 13, 2018

SELL
$71.28 - $78.92 $361,532 - $400,282
-5,072 Reduced 5.09%
94,559 $7.3 Million
Q2 2018

Aug 10, 2018

SELL
$64.88 - $75.68 $1.59 Million - $1.85 Million
-24,438 Reduced 19.7%
99,631 $7.06 Million
Q1 2018

May 14, 2018

BUY
$72.84 - $88.8 $273,587 - $333,532
3,756 Added 3.12%
124,069 $9.35 Million
Q4 2017

Feb 09, 2018

BUY
$71.15 - $83.52 $1.55 Million - $1.82 Million
21,813 Added 22.15%
120,313 $8.62 Million
Q3 2017

Oct 20, 2017

SELL
$72.11 - $85.47 $12.7 Million - $15 Million
-176,083 Reduced 64.13%
98,500 $7.98 Million
Q3 2017

Oct 18, 2017

BUY
$72.11 - $85.47 $19.8 Million - $23.5 Million
274,583
274,583 $29.2 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.